 | Up a level |
King, J, Palmer, DH 
ORCID: 0000-0002-7147-5703, Johnson, P ORCID: 0000-0003-1404-0209, Ross, P, Hubner, RA, Sumpter, K, Darby, S, Braconi, C, Iwuji, C, Swinson, D et al (show 8 more authors)
(2017)
Sorafenib for the Treatment of Advanced Hepatocellular Cancer - a UK Audit.
Clinical oncology (Royal College of Radiologists (Great Britain)), 29 (4).
pp. 256-262.
Edeline, J, Blanc, J-F, Johnson, P ORCID: 0000-0003-1404-0209, Campillo-Gimenez, B, Ross, P, Ma, YT, King, J, Hubner, RA, Sumpter, K, Darby, S et al (show 8 more authors)
(2016)
A multicentre comparison between Child Pugh and Albumin‐Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma.
Liver international : official journal of the International Association for the Study of the Liver, 36 (12).
pp. 1821-1828.
Palmer, DH ORCID: 0000-0002-7147-5703, Ma, YT, Peck-Radosavljevic, M, Ross, P, Graham, J, Fartoux, L, Deptala, A, Studeny, M, Schnell, D, Hocke, J et al (show 2 more authors)
(2018)
A multicentre, open-label, phase-I/randomised phase-II study to evaluate safety, pharmacokinetics, and efficacy of nintedanib vs. sorafenib in European patients with advanced hepatocellular carcinoma.
British Journal of Cancer, 118 (9).
pp. 1162-1168.